You are here

Phase 3 Trial of Veronate To Continue, Treatment for the Prevention of Hospital-Associated Infections in Premature Infants

ATLANTA, Dec. 5 /PRNewswire-FirstCall/ -- Inhibitex, Inc. (NASDAQ:INHX) announced today that its independent Data Safety Monitoring Board (DSMB) met as scheduled to review clinical data from the Company's 2,000 patient pivotal Phase III clinical trial of Veronate for the prevention of hospital-associated infections in premature, very low birth weight infants. The purpose of the DSMB meeting was to review available data once 1,500 enrolled infants had completed their 70 day follow-up period in order to assess the safety profile of Veronate and the trial's overall design parameters. Based upon its review, the DSMB unanimously recommended that the trial should be completed without modification.

"Until the data is unblinded, these communications from the DSMB are our only insight into the potential outcome of this trial, so we are very encouraged with its recommendation," stated William D. Johnston, Ph.D., President and Chief Executive Officer of Inhibitex, Inc. "While we cannot predict the ultimate result of this ongoing trial, the DSMB decision further reinforces our confidence regarding our assumed rate of infection, the adequacy of the statistical design and the powering of the trial relative to its primary endpoint. We continue to expect that top line results from the trial will be available in the second quarter of 2006."

The Company previously reported that the same DSMB had met and reviewed similar clinical data after 500, 1,000 and 1,500 patients had been enrolled in the trial, and in each case, unanimously recommended that the trial should continue as designed, without modification.

About Veronate
Veronate, a novel, antibody-based investigational drug being developed to prevent hospital-associated infections in premature, very low birth weight infants weighing 500-1,250 grams at birth, is the Company's most advanced product candidate. The primary endpoint of the pivotal Phase III trial is to demonstrate efficacy in the prevention of hospital-associated infections due to Staphylococcus aureus (S. aureus) in this infant population Secondary endpoints include a reduction in the frequency of hospital-associated infections due to Candida species (fungus) and Coagulase-negative staphylococci (CoNS), and a reduction in the mortality rate. Veronate has been granted both Fast Track designation and Orphan Drug status in the United States and has been recommended for Orphan Medicinal Product designation in Europe. The Company has retained all world-wide rights to Veronate and, if approved, anticipates commercializing it independently in the United States.

Source: Inhibitex, Inc.

Recent Headlines

Potential contamination could lead to supply chain disruptions
Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs